Background and Purpose-Risk of recurrent stroke is high in the first few weeks after transient ischemic attack or stroke and clinical risk prediction tools have only limited accuracy, particularly after the hyperacute phase. Previous studies of the predictive value of biomarkers have been small, been done in selected populations, and have not concentrated on the acute phase or on intensively treated populations. We aimed to determine the predictive value of a panel of blood biomarkers in intensively treated patients early after transient ischemic attack and stroke. Methods-We studied 14 blood biomarkers related to inflammation, thrombosis, atherogenesis, and cardiac or neuronal cell damage in early transient ischemic attack or ischemic stroke in a population-based study (Oxford Vascular Study). Biomarker levels were related to 90-day risk of recurrent stroke as hazard ratio (95% confidence interval) per decile increase, adjusted for age and sex. Results-Among 1292 eligible patients, there were 53 recurrent ischemic strokes within 90 days. There were moderate correlations (r=0.40-0.61; P<0.0001) between the inflammatory biomarkers and between the cell damage and thrombotic subsets. Associations with risk of early recurrent stroke were weak, with significant associations limited to interleukin-6 (adjusted hazard ratio, 1.12; 1.01-1.24; P=0.033) and C-reactive protein (adjusted hazard ratio, 1.15; 1.02-1.30; P=0.022) after adjusting for age, sex, hypertension, smoking, and diabetes mellitus although P-selectin seemed to predict stroke after transient ischemic attack (adjusted hazard ratio, 1.28; 1.00-1.63; P=0.046). Conclusions-In the largest study to date, we found limited predictive use for early recurrent stroke for a panel of inflammatory, thrombotic, and cell damage biomarkers. (Stroke. 2014;45:00-00.)
P rediction of early recurrent stroke after a transient ischemic attack (TIA) or stroke would be clinically useful. Clinical risk scores, such as the ABCD (age blood pressure, clinical features, duration of symptoms) system, are of some predictive value after TIA, 1 particularly when carotid and brain imaging are incorporated, 2, 3 but better prediction is required and there are no widely used and validated scores to predict early recurrence after stroke. Use of blood biomarkers could improve predictive power of risk scores and help to target secondary prevention. Several biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer, have been shown to predict long-term risk of cardiovascular events in primary prevention populations, [4] [5] [6] but those biomarkers studied in the secondary prevention setting after stroke have generally not been found to add to the overall predictive power of clinical risk scores for long-term risk of recurrent events. [7] [8] [9] [10] CRP, IL-6, and fibrinogen have been associated with the long-term (>3 years of outcome) risk of recurrent stroke 11 and CRP was predictive for stroke and other vascular events, 12 but there have been few small studies of biomarkers in the prediction of early stroke recurrence after TIA and stroke. These studies have used different outcomes and have reported conflicting results about the predictive value of markers, such as IL-6 and CRP. [13] [14] [15] [16] [17] There have, therefore, been calls for larger studies to help reduce publication-bias and type-2 error in determining the role of biomarkers in diagnosis and risk prediction. 13 We therefore aimed in this large prospective populationbased study to establish whether a panel of biomarkers related to inflammation, thrombosis, atherogenesis, and cardiac or neuronal function was of prognostic value for the risk of recurrent stroke within 90 days of TIA or stroke in patients on current best medical therapy. The panel was chosen based on evidence of possible prognostic value from previous studies. [11] [12] [13] [14] [15] [16] [17] [18] The inflammatory biomarkers used were IL-6, CRP, tumor necrosis factor receptor-1, and neutrophil gelatinaseassociated lipocalin. Thrombotic biomarkers were thrombomodulin, fibrinogen, P-selectin, D-dimer, von Willebrand factor antigen (VWF), and protein Z (PZ). In addition, antiphosphorylcholine, an anti-atherogenic antibody, was included as low levels may be predictive of stroke. 19 Markers of cardiac or neuronal function and injury and neurone regeneration used were heart type fatty acid-binding protein, neurone-specific enolase, and brain-derived neurotrophic factor (BDNF).
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Methods

Patients and Samples
The Oxford Vascular Study (OXVASC) is a large population-based study of the incidence of all acute vascular events, including TIA, strokes, acute coronary syndromes, and peripheral vascular events. The methods are described in detail elsewhere, 20 and the study was approved by the Oxfordshire Research Ethics Committee. The OXVASC population consists of 92 728 individuals registered with 100 primary-care physicians in Oxfordshire, United Kingdom.
Patients with TIA or stroke were identified by multiple methods of ascertainment, which have been shown previously to be near complete. 21 Briefly, multiple overlapping methods of hot and cold pursuit were used to achieve near-complete ascertainment of all individuals presenting to medical attention with TIA or stroke. 21 Methods of hot pursuit include 1. A 7-day, open-access TIA service to which participating general practitioners and the local accident and emergency department send all individuals with suspected TIA or minor stroke whom they would not normally admit to hospital, with emergency provision at weekends supplementing a weekday clinic. 2. Daily searches of admissions to the stroke unit, medical, neurology, and other relevant wards. 3. Daily searches of the local accident and emergency department and eye hospital attendance register.
All patients provided written informed consent and were seen by study physicians as soon as possible after their initial presentation. Relatives provided written assent and clinical details in those unable to provide written consent. A detailed history was obtained from each patient with a standardized questionnaire. This included date of symptom onset, duration and type of symptoms, baseline characteristics, and time of first seeking medical attention. All cases were subsequently reviewed by the study senior neurologist (P.M.R.) and classified as stroke or other condition using standard definitions. 22 Assessments were made for severity of event using the National Institute of Health Stroke Scale 23 and clinical features. Events were classified as minor stroke if there was a focal neurological deficit lasting >24 hours and a National Institute of Health Stroke Scale score ≤3 at time of assessment by a study physician. Vascular evaluation was performed using computed tomography, MR, or catheter angiography as clinically appropriate. Recurrent vascular events were identified by face-to-face follow-up at 1, 6, and 12 months and by the ongoing case ascertainment in the OXVASC Study. 21 All patients were started on appropriate secondary preventive treatment on the day of the initial clinical assessment or after hospital admission, which generally included antithrombotic treatment, a statin (usually simvastatin 40 mg daily) and antihypertensive medication (usually an angiotensin-converting enzyme inhibitor and indapamide initially) according to the Early Use of Existing Preventative Strategies for Stroke (EXPRESS) study protocol. 24 Antithrombotic treatment was aspirin (300 mg loading dose followed by 75 mg daily) in all cases not requiring anticoagulation, with the addition of clopidogrel (300 mg loading dose followed by 75 mg daily) in patients with an ABCD score ≥4 or with recently symptomatic large artery stenosis, as per the EXPRESS study protocol. 24 Nonfasting blood samples were taken at the time of first assessment and included serum, 3.2% buffered tri-sodium citrate plasma and lithium heparin plasma (Vacutainer tubes; Becton Dickinson, United Kingdom). Samples were centrifuged at 3000 g for 10 minutes, and aliquots of serum and plasma were stored at -80°C before analysis when they were thawed for use at 37°C for 10 minutes. All times from sampling to freezing were documented, typically within 4 hours of taking.
Assay Methods
A Randox Evidence Investigator Biochip multiple immunoassay system (Randox Laboratories Ltd, Co Antrim, United Kingdom) using lithium heparin plasma simultaneously measured biomarkers via 2 panels: cerebral array I consisted of IL-6, heart type fatty acid-binding protein, and brain-derived neurotrophic factor and cerebral array II BDNF indicates brain-derived neurotrophic factor; CRP, C-reactive protein; hFABP, heart type fatty acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; NSE, neurone-specific enolase; TNF, tumor necrosis factor; and VWF, von Willebrand factor antigen.
*Total samples analyzed differ because of constraints on sample size and †where warfarin therapy may have affected protein synthesis, and ‡according to the materials available.
by guest on January 16, 2018 http://stroke.ahajournals.org/ Downloaded from consisted of CRP, neutrophil gelatinase-associated lipocalin, soluble tumor necrosis factor receptor-1, neurone-specific enolase, and thrombomodulin. All assays underwent reproducibility studies using an internal control of pooled normal lithium heparin plasma in addition to manufacturers control materials. Levels of fibrinogen by the Clauss clotting method and D-dimer and VWF antigen by immunoturbidometric assays were measured in citrated plasma using an automated coagulation analyzer STA (Sta-Liatest VWF and Sta-Liatest D-dimer, Diagnostica Stago, Asniers, France). These assays had well-defined internal quality control and external control through participation in national quality assurance schemes. Commercial ELISA kits were used to assay human P-selectin (R&D Systems, United Kingdom) and PZ (Diagnostica Stago, France). Serum samples were used for antiphosphorylcholine antibodies (CVDefine; Athera Biotechnologies AB, Stockholm, Sweden), adhering to manufacturers recommendations. Percentage of intra-and intercoefficients of variation of each assay are shown in Table 1 . All assays were performed blind to study status.
Statistical Analysis
Data were analyzed using SPSS for windows version 20. Spearman rank correlations were calculated to determine the correlation between variables. Cox Regression was used to determine the hazard ratio (HR) and corresponding 95% confidence interval (CI) for the risk of each decile of biomarker level (compared with the first/lowest) to recurrent ischemic stroke in all patients within 90 days. Bonferroni adjustment for multiple testing was applied to the statistical significance of these risk associations (based on 14 biomarkers tested). Any interaction between prognostic value and severity of baseline event was explored by dividing the cohort into TIA versus stroke. The effect of time from the event to sampling on the predictive value of biomarker levels was assessed by performing the analysis on patients in whom the sample was taken within 7 days of the initial event. The decile trend was adjusted for age and sex and any biomarkers that remained significant were further adjusted for hypertension, current smoking, diabetes mellitus, and body mass index. The area under the receiver operating characteristic curve was determined for biomarkers with statistically significant univariate risk associations, and the linearity of associations was assessed by HRs across tertile groups.
Results
A total of 1292 consecutive consenting eligible patients were recruited. Table 2 shows the baseline characteristics at the time of the event for all patients classified as TIA and stroke. Mean (SD) age was 73.1 (13.3) years, 48% (n=617) were men, and hypertension was the most prevalent risk factor being found in 59% (n=767). The median (interquartile range) days from event to sampling were 5 (3-11) days. A maximum of 1207 samples were analyzed by the Randox panels composed of 401 TIA and 806 stroke. Numbers were limited by inadequate sample volumes in 79 patients and assay failure in 6. Thrombotic markers were measured in a maximum of 1072 patients after exclusion of cases with inadequate sample volumes (n=152) and anticoagulant therapy (n=68).
The correlations between biomarker levels are shown in Table 3 . There was good cross-correlation within the subset of inflammatory markers, the greatest was between CRP and IL-6 (0.58). Within the thrombotic subset fibrinogen and VWF correlated with each other (0.41) but to a lesser degree to D-dimer and none of these factors correlated with P-selectin, thrombomodulin, or PZ. Moderate correlations (P<0.0001) existed between the biomarker subsets, the greatest was for CRP and fibrinogen (0.61), CRP and VWF (0.47). Markers of neurone cell damage neurone-specific enolase and brainderived neurotrophic factor correlated with each other (0.48) and the inflammatory marker neutrophil gelatinase-associated lipocalin (0.39 and 0.45, respectively) but not to the same degree with heart type fatty acid-binding protein, which itself correlated well with the inflammatory markers, particularly soluble tumor necrosis factor receptor-1 (0.54). Antiphosphorylcholine did not correlate with any other biomarker.
After sampling and within 90 days of follow-up, there were 53 recurrent ischemic strokes. There were also 17 nonstroke deaths in TIA and minor stroke, all of which were nonvascular (8 cancer, 7 respiratory, and 2 other). The HR per decile increase in biomarker (HR; 95% CI) for a recurrent stroke for all patients, TIA, and all patients with stroke adjusted for age and sex is shown in Table 4 . For all patients, 2 inflammatory biomarkers were predictive for a recurrent stroke, IL-6 (HR, 1.12; 95% CI, 1.01-1.24; P=0.035) and CRP (1.16; 1.02-1.30; P=0.019). The areas under the receiver operating characteristic curve for prediction of stroke were 0.60 (95% CI, 0.52-0.68; P=0.015) for CRP and 0.59 (0.51-0.67; P=0.029) for IL-6. When fully adjusted for age, sex, hypertension, smoking, and diabetes mellitus, the On analyses limited to patients with samples (n=829) taken within 7 days of the event, predictive value for 90-day risk of stroke was again limited to CRP (fully adjusted HR, 1.20; 1.03-1.39; P=0.018) and IL-6 (1.12; 0.99-1.26; P=0.06).
For no biomarker, there was a statistically significant difference in predictive value between patients with TIA and stroke, but P-selectin was predictive of risk of recurrent stroke in patients with TIA (fully adjusted HR, 1.28; 1.00-1.63; P=0.046) and CRP was most predictive in patients with stroke (1.16;1.01-1.34; P=0.041). However, on adjustment for multiple comparisons because of the large numbers of biomarkers measured, all the weak associations were lost.
Discussion
In the largest published study to date in patients with TIA and stroke, no single biomarker stood out as being a strong independent predictor of the early risk of recurrent stroke in a cohort of patients on current best medical therapy. Although our data on correlations between biomarkers should be helpful in refining biomarker selection in future studies and panel designs, we did not find that the biomarkers that we chose were likely to be clinically useful in routine practice. The inflammatory biomarkers IL-6 and CRP were weakly predictive of recurrent stroke, but the marginally statistically significant results must be interpreted with caution because of the large number of biomarkers studied and the loss of significance when these associations were adjusted for multiple comparisons.
Our data add to previous reports of associations with severity of prior stroke. 25, 26 In one previous study in 194 patients with TIA, CRP was weakly predictive of the 2-year risk of stroke 15 but did not predict 90-day risk in another study of 167 patients with TIA although this was based on only 5 recurrent strokes. 16 CRP has been used for the prediction of cardiovascular events in primary prevention settings but has not been considered to be a sufficiently strong independent predictor to be useful in clinical practice. 13, 25 Several studies have related inflammatory markers to shortterm outcome after acute stroke. 14, 17, 27 Although some associations with poor outcome have been reported, these seem mainly to reflect reverse causation (ie, more severe strokes have greater acute phase inflammatory responses), rather than any association with risk of recurrent events. Our cohort was predominantly made of patients with TIA and minor stroke in whom recurrent stroke rather than severity of event is less prone to reverse causation. There is some evidence that biomarker profiles differ between lacunar stroke and other ischemic stroke subtypes, 28 IL-6 is elevated in cardioembolic stroke compared with lacunar stroke, 29 and CRP may be a long-term prognostic indicator after lacunar stroke. 12 However, all of these studies and our current study were underpowered to stratify predictive values by stroke subtype.
P-selectin levels were possibly predictive of recurrent stroke in patients with TIA in our study, but this finding should be interpreted cautiously and requires further validation. P-selectin has been associated with hypertension and stroke risk in atrial fibrillation, 30, 31 but there are too few studies to draw any clinically useful conclusions. A systematic review found that fibrinogen and D-dimer but not P-selectin were associated with poor outcome after stroke. 10 In contrast to some of the previous literature, mainly on stroke outcome and long-term risk prediction, we found no associations with early recurrent risk for anti-phosphorylcholine, 32, 33 heart type fatty acid-binding protein, 17 fibrinogen, 11, 34, 35 D-dimer, 36 or VWF. 37 PZ seems to be associated with ischemic stroke 18 but had not previously been validated as a predictor of recurrent stroke. As a cofactor in the coagulation cascade, subject to feedback mechanisms, any deficiency of PZ is feasibly compensated for in the regulation of thrombin, thereby reducing its significance for early stroke.
We consider our findings to be valid, but our study did have some shortcomings. First, although to our knowledge it is the largest study of its kind, statistical power was limited by the 53 recurrent stroke outcomes at 90 days. We were therefore unable to determine predictive power stratified by TOAST (Trial of Org 10 172 in Acute Stroke Treatment) subtype. Second, patients were sampled as soon as possible after clinical presentation, but it is possible that peak levels of some markers may have been missed, 9 although previous work suggests that delay to sampling is unlikely to have affected our findings for IL-6 or CRP. 7 Moreover, when analysis was limited to samples from patients within 7 days, the associations of biomarker levels were similar (slightly weaker for IL-6). Third, our high rates of use of antiplatelet and statin treatment after TIA and stroke could have affected the predictive value of inflammatory and thrombotic markers, and we were not able to determine the predictive value of biomarkers in patients not on medication. However, our findings should be generalizable to routine clinical practice in which these medications should be prescribed to the majority of patients.
In conclusion, we were unable to validate previous suggestions that blood biomarkers might aid prediction of early recurrent stroke. Additional studies would be required to determine predictive values within specific ischemic stroke subtypes, but routine measurement of the biomarkers that we studied is not currently justified in routine clinical practice. BDNF indicates brain-derived neurotrophic factor; CRP, C-reactive protein; hFABP, heart type fatty acid-binding protein; IL-6, interleukin-6; NGAL, neutrophil gelatinase-associated lipocalin; NSE, neurone-specific enolase; TIA, transient ischemic attack; TNFR-1, tumor necrosis factor receptor-1; and VWF, von Willebrand factor antigen. by guest on January 16, 2018 http://stroke.ahajournals.org/ Downloaded from
